Thanks Monti - it's all there, Pharma has been knocking on the...

Thanks Monti - it's all there, Pharma has been knocking on the door since the P2 results were announced.

We just need to read between the lines.

- Delay in EMA PIP process...on purpose by ANP imo.
- Pivot to get FDA guidance asap!
- Push to get "Fast Track designation" with FDA
- Alignment of endpoints and trial design between EMA and FDA
- The FDA approval of higher doses for Phase 2B
- Lack of detail about the monkey tox studies logistics / funding.

- Dr Voit as PI for Phase 2B - is patent owner of Sarapta's GT 'micro-dystrophin' IP
- Lack of 'senior appointments' so far, sans Dr Gittleson...mentioned at AGM
- Delay of 'new in indications' news

"The Company would advise the market should these interactions lead to a material transaction."

The ducks are aligned with both EMA and FDA agreeing to same endpoints, dose regiment, ambulant and non-ambulant population...throw in maybe a combination therapy?

Now it's about the $$$...and Morgans in their research note are estimating a $350m licensing deal.

That partnership deal needs to be larger given the opportunity.

BUT then, if you were Sarepta...you might as well try a $2.50 cash and script offer.

Sarepta has the most to lose if ANP succeeds.
.